EUVIMEDEUVIMED entdecken
Crossref

Targeting Pain Early: Pharmacological Innovations And Challenges in the Treatment of Pediatric Headaches

Avinash Chandra, Yubin Wang, Jiahao Li, Sudikshya Acharya, Nabina Sharma, Ayush Chandra

SN Comprehensive Clinical Medicine · 05.11.2026 · 8 (1)

DOI: 10.1007/s42399-026-02838-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Avinash Chandra und 5 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric headaches encompass migraine, tension-type headache, less common primary disorders, and headaches attributed to underlying disease or injury. Timely treatment depends on recognizing the headache type and matching therapy to pediatric evidence. This narrative review examines acute and preventive pharmacotherapy, emerging treatments, and prescribing challenges across these conditions, with a targeted literature update through 2 October 2026. Simple analgesics have a role in migraine and tension-type headache, whereas triptan efficacy and age-specific approvals principally concern migraine. Conventional migraine preventives require interpretation alongside substantial placebo responses, and cognitive behavioral therapy can strengthen multimodal care. Fremanezumab has randomized pediatric evidence and a US indication for episodic migraine prevention at ages 6–17 years and body weight of at least 45 kg. These findings do not establish efficacy for other headache diagnoses. Tension-type headache prevention, cluster headache, and new daily persistent headache rely more heavily on consensus or observational evidence; indomethacin-responsive syndromes require diagnosis-specific treatment. Secondary headaches require management of the underlying cause, with phenotype-guided care for persistent post-traumatic headache and attention to medication overuse. Other calcitonin gene-related peptide (CGRP)-targeted therapies, gepants, lasmiditan, pituitary adenylate cyclase-activating polypeptide (PACAP), and substance P occupy distinct stages of development. Linking headache diagnosis, evidence type, pediatric dosing, and regulatory status provides a practical framework for early, individualized treatment and improved daily functioning.

Zitieren

APA

Chandra, A., Wang, Y., Li, J., Acharya, S., Sharma, N., & Chandra, A. (2026). Targeting Pain Early: Pharmacological Innovations And Challenges in the Treatment of Pediatric Headaches. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02838-2

Vancouver

Chandra A, Wang Y, Li J, Acharya S, Sharma N, Chandra A. Targeting Pain Early: Pharmacological Innovations And Challenges in the Treatment of Pediatric Headaches. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02838-2

BibTeX
@article{Chandra2026,
  author = {Chandra, Avinash and Wang, Yubin and Li, Jiahao and Acharya, Sudikshya and Sharma, Nabina and Chandra, Ayush},
  title = {Targeting Pain Early: Pharmacological Innovations And Challenges in the Treatment of Pediatric Headaches},
  journal = {SN Comprehensive Clinical Medicine},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1007/s42399-026-02838-2}
}
Kostenlos starten →